Companies in the News

Omniome Completes $60 Million Series B Financing To Advance Novel Genomic Sequencing Technology

SAN DIEGO, July 30, 2018 /PRNewswire/ -- Omniome, Inc., developer of an innovative new DNA sequencing platform, today announced it has raised an additional $60 million with the completion of its Series B financing. The funding round was led by Decheng Capital and Hillhouse Capital Group, joined by Lam Research Capital and Nan Fung Life Sciences as well as current investors ARCH Venture Partners, Domain Associates, Biomatics Capital Partners and Altitude Life Science Ventures. "We have been able to validate the tremendous power of our proprietary sequencing biochemistry. Now we are directing our efforts on product development to rapidly advance our first commercial instrument prototypes," sai

eFFECTOR Initiates Dosing of eFT508 (tomivosertib) in a Phase 2 Add-on (CPI-A) Trial in Combination

SAN DIEGO, July 27, 2018 — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it has dosed the first patient in a Phase 2 clinical trial of eFT508 (tomivosertib), the company’s oral, small molecule inhibitor of MNK1/2, added on to patients already receiving an FDA-approved anti-PD-1 or anti-PD-L1 checkpoint inhibitor, which may include Keytruda, Opdivo, Tecentriq, Bavencio or Imfinzi. Patients taking one of these checkpoint inhibitors in an approved indication who are experiencing an insufficient response to checkpoint inhibitor therapy alone are eligible for enrollment in this study. At the ti

Gossamer Bio Announces $230 Million Series B Financing

Co-Founder & current Chief Operating Officer Sheila Gujrathi, M.D., appointed Chief Executive Officer Co-Founder & current Chief Executive Officer Faheem Hasnain becomes Executive Chairman SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio Inc. (“Gossamer Bio”), a privately held biotechnology company focused on the discovery and development of novel and differentiated therapeutic products to address high unmet need, today announced the closing of a $230 million Series B preferred stock financing led by Hillhouse Capital. New investors participating in this financing include among others, a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), Invus, The Baupost Group and Polaris Partne

Indigo Wheat™ Demonstrates Continuous Improvement with Significant Yield Gains in Second Commercial

Indigo Wheat™ demonstrated average yield gains of 19% in low yielding conditions and 13% across all conditions Improving upon last year’s yield gains of 16% in low yielding conditions and 8% across all conditions, 2018 reflects year-over-year improvement, validating research and development approach Boston, Massachusetts, July 10, 2018 – Indigo Ag, Inc., a company dedicated to harnessing nature to help farmers sustainably feed the planet, has released an early view on yield data from its microbial seed treatment for wheat. In its second commercial season, Indigo Wheat™ demonstrated an average yield uplift of 13% in side-by-side trials held on 24 fields, with four popular seed varieties acros